The Asia Pacific Diabetic Retinopathy Market would witness market growth of 11.9% CAGR during the forecast period (2021-2027).
The retina can eventually separate from the back of the eye due to scar tissue formed by the development of new blood vessels. If the new blood vessels obstruct the usual flow of fluid out of the eye, the tension in the eyeball might build up. Glaucoma is caused by a buildup of fluid on the optic nerve, the nerve that transmits images from the eye to the brain.
The more advanced form of the illness is proliferative diabetic retinopathy (PDR). Circulation difficulties are depriving the retina of oxygen at this point. As a result, new and fragile blood vessels in the retina and the vitreous, the gel-like substance that fills the back of the eye, may begin to form. Blood may leak from the developing blood vessels into the vitreous, blurring vision. PDR can also cause retinal detachment as a result of scar tissue production, as well as the occurrence of glaucoma. Progressive vision loss is one of the symptoms, especially in those who are not appropriately monitored or treated. According to data published by Columbia University, the length of diabetes, which increases the incidence of retinopathy by 65 percent, is one of the key risk factors for PDR.
The regional diabetic retinopathy market is increasing because of the rising number of patients with diabetes in Asia-Pacific. In addition, emerging economies in the Asia-Pacific area, such as Japan and China, would develop significantly due to the increasing disposable income of the regional population, a substantial aging population, increased investment for research and development activities for diabetes, and diagnostic innovation. Due to high medical expenses, the Chinese market is growing at a healthy speed. Although Japan is one of the largest markets in the Asia-Pacific region. In addition, the rising adoption of Laser therapy is anticipated to accelerate the demand for diabetic retinopathy treatment.
Due to a huge patient pool along with the advent of technologies and innovation in diagnostic approaches and government health insurance regulations, the diabetic retinopathy market in the Asia Pacific area is booming. According to a report published in the Journal of Diabetology in 2018, over 80 million people in the Asia Pacific area were suffering from diabetes in 2017, with the number anticipated to rise to 151 million by 2045.
The China market dominated the Asia Pacific Diabetic Retinopathy Market by Country in 2020, and would continue to be a dominant market till 2027; thereby, achieving a market value of $583.1 Million by 2027. The Japan market is poised to grow at a CAGR of 11.3% during (2021 - 2027). Additionally, The India market would exhibit a CAGR of 12.7% during (2021 - 2027).
Based on Type, the market is segmented into Proliferative and Diabetic Macular Edema (DME). Based on Treatment Type, the market is segmented into Anti VEGF Drug, Steroid Implants, Laser Surgeries, and Vitrectomy. Based on countries, the market is segmented into China, Japan, India, South Korea, Singapore, Malaysia, and Rest of Asia Pacific.
Free Valuable Insights: The Worldwide Diabetic Retinopathy Market is Projected to reach USD 7.7 Billion by 2027, at a CAGR of 11.3%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Allergan PLC (Abbvie, Inc.), Bayer AG, Alimera Sciences, Inc., Novartis AG, Pfizer, Inc., F-Hoffmann-La Roche Ltd., Ampio Pharmaceuticals-us, KOWA CO., LTD., Regeneron Pharmaceuticals, Inc., and Bausch Health Companies, Inc.
By Type
By Treatment Type
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
